Sam Jackson

Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults

Sam Jackson, Joseph R. Lentino, James Kopp et al. · Vaccine · 2017 · 192 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +15

Safety, Tolerability, and Feasibility of Young Plasma Infusion in the Plasma for Alzheimer Symptom Amelioration Study

Sharon J. Sha, Gayle K. Deutsch, Lü Tian et al. · JAMA Neurology · 2018 · 111 citations · Full text

Medicine, Neurology, Pharmacology +17

Safety of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant in adults

Randall N. Hyer, Darren K. McGuire, Biao Xing et al. · Vaccine · 2018 · 59 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Immunogenicity of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in subpopulations of healthy adults 18–70 years of age

Julia M. Janssen, Sam Jackson, William L. Heyward et al. · Vaccine · 2015 · 44 citations

Veterinary Medicine, Immunology, Infectious Diseases +15

First‐in‐Human Study With the Inhaled TLR9 Oligonucleotide Agonist AZD1419 Results in Interferon Responses in the Lung, and Is Safe and Well‐Tolerated

Sam Jackson, Albert F. Candia, Stephen Delaney et al. · Clinical Pharmacology & Therapeutics · 2017 · 30 citations

Life Sciences, Immunology, Pharmacology +15